| NWS |
Report |
Total Segment EBITDA (Q4 FY26) |
BEAT |
pred ~$362M vs. cons ~$345M |
MEDIUM |
| NWS |
Report |
Adjusted Diluted EPS (Q4 FY26) |
BEAT |
pred ~$0.17 vs. cons ~$0.15 |
MEDIUM |
| NWS |
Report |
Dow Jones Segment EBITDA (Q4 FY26) |
BEAT |
pred ~$168M vs. cons ~$158M |
MEDIUM |
| NWS |
Guide |
Full-Year FY2026 Free Cash Flow |
BETTER |
guide ~$660M vs. cons ~$625M (FY2026 full-year, reported alongside Q4) |
MEDIUM |
| NWS |
Guide |
Dow Jones margin trajectory toward $1B EBITDA target |
UNCHANGED |
guide ~24% exit margin vs. cons ~23.8% (FY2026 exit rate, reiterating 5-yr $1B target) |
LOW |
| NWS |
Guide |
Capital returns / buyback pace commentary |
BETTER |
guide ~$650M FY26 total repurchases vs. cons ~$600M implied run-rate (FY2026 full-year) |
MEDIUM |
| NWS |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.2% |
— |
MEDIUM |
| NWS |
Return |
5-day cumulative residual |
-0.8% (FADE) |
Stock is already up ~17% off June lows heading into print, pricing in a 13th straight EBITDA growth quarter and continued Dow Jones/AI licensing momentum, so a modest beat is largely discounted. Tougher FY2027 comps (Book Publishing frontlist lapping, News Media/California Post ongoing drag, and uncertain Anthropic settlement cash timing) likely temper forward estimate revisions even if headline Q4 numbers beat, causing initial pop to partially fade over the following days as analysts model more conservative out-period growth. |
LOW |